Estudios Actuales

Título	Condition	Inclusion Criteria	Descripción
Oral Medication Added to Long-acting Insulin	Type 2 diabetes	HbA1c 7-10%	52-week trial for people on a basal insulin and metformin.
Monthly Diabetes Therapy	Type 2 diabetes	HbA1c 6.8-10%	6-month study with a once-monthly medication for people taking metformin
Daily Oral Therapy	Type 2 diabetes	HbA1c 7-11%	12-week trial of the effects of a medication approved for another condition on diabetes control.
Neuropathy in Diabetes	Type 1 diabetes Type 2 diabetes	HbA1c < 10%	15-month study of a potential therapy for diabetes nerve damage in both type 1 and type 2 diabetes
Weekly vs. Daily Diabetes Therapy	Type 2 diabetes	HbA1c 7-10%	40-week study of weekly compared to daily therapy for diabetes that may be associated with weight loss
HALO 1	Type 1 diabetes	HbA1c 6.7-8.2%	31-week trial of new ultra-fast meal insulin in type 1 diabetes.
HALO 2	Type 2 diabetes	HbA1c 7-8.5%	31-week study of a new ultra-fast meal insulin for people with type 2 diabetes already taking meal insulin for > 1 year.
Blood Glucose Meters	Type 1 diabetes Type 2 diabetes		Help us test new glucose meters.
Continuous Glucose Monitors	Type 1 diabetes		Help us test new continuous glucose monitors. You would typically wear an investigational device for 1 to 2 weeks and be compensated based on your time.
Insulin Pump	Type 1 diabetes		Help us test new insulin pumps and pump features. You will be compensated based on your time.